GemVax&KAEL Co.,Ltd. (KOSDAQ:082270)

GemVax&KAEL Statistics

Total Valuation

GemVax&KAEL has a market cap or net worth of KRW 2.87 trillion. The enterprise value is 2.92 trillion.

Market Cap	2.87T
Enterprise Value	2.92T

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

GemVax&KAEL has 41.09 million shares outstanding. The number of shares has increased by 0.91% in one year.

Current Share Class	41.09M
Shares Outstanding	41.09M
Shares Change (YoY)	+0.91%
Shares Change (QoQ)	+0.39%
Owned by Insiders (%)	1.49%
Owned by Institutions (%)	6.57%
Float	30.45M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	47.54
PB Ratio	68.35
P/TBV Ratio	73.92
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-47.42
EV / Sales	48.41
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-104.76

Financial Position

The company has a current ratio of 0.65, with a Debt / Equity ratio of 1.76.

Current Ratio	0.65
Quick Ratio	0.49
Debt / Equity	1.76
Debt / EBITDA	n/a
Debt / FCF	-2.65
Interest Coverage	-4.83

Financial Efficiency

Return on equity (ROE) is -106.33% and return on invested capital (ROIC) is -12.80%.

Return on Equity (ROE)	-106.33%
Return on Assets (ROA)	-9.69%
Return on Invested Capital (ROIC)	-12.80%
Return on Capital Employed (ROCE)	-22.72%
Revenue Per Employee	314.24M
Profits Per Employee	-320.79M
Employee Count	192
Asset Turnover	0.40
Inventory Turnover	4.92

Taxes

Income Tax	-1.09B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +538.03% in the last 52 weeks. The beta is 1.02, so GemVax&KAEL's price volatility has been similar to the market average.

Beta (5Y)	1.02
52-Week Price Change	+538.03%
50-Day Moving Average	39,809.00
200-Day Moving Average	25,208.45
Relative Strength Index (RSI)	88.69
Average Volume (20 Days)	320,539

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GemVax&KAEL had revenue of KRW 60.33 billion and -61.59 billion in losses. Loss per share was -1,551.71.

Revenue	60.33B
Gross Profit	19.49B
Operating Income	-23.10B
Pretax Income	-62.68B
Net Income	-61.59B
EBITDA	-18.70B
EBIT	-23.10B
Loss Per Share	-1,551.71

Balance Sheet

The company has 21.57 billion in cash and 73.79 billion in debt, giving a net cash position of -52.23 billion or -1,271.03 per share.

Cash & Cash Equivalents	21.57B
Total Debt	73.79B
Net Cash	-52.23B
Net Cash Per Share	-1,271.03
Equity (Book Value)	41.97B
Book Value Per Share	1,021.28
Working Capital	-20.49B

Cash Flow

In the last 12 months, operating cash flow was -25.13 billion and capital expenditures -2.75 billion, giving a free cash flow of -27.88 billion.

Operating Cash Flow	-25.13B
Capital Expenditures	-2.75B
Free Cash Flow	-27.88B
FCF Per Share	-678.42

Margins

Gross margin is 32.30%, with operating and profit margins of -38.28% and -102.09%.

Gross Margin	32.30%
Operating Margin	-38.28%
Pretax Margin	-103.89%
Profit Margin	-102.09%
EBITDA Margin	-30.99%
EBIT Margin	-38.28%
FCF Margin	n/a

Dividends & Yields

GemVax&KAEL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.91%
Shareholder Yield	n/a
Earnings Yield	-2.15%
FCF Yield	-0.97%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GemVax&KAEL has an Altman Z-Score of 2.39 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.39
Piotroski F-Score	1